Heart Failure Research

Heart failure, also known as congestive heart failure or CHF, is an inability of the heart to pump sufficient blood around the body.Heart failure typically occurs secondary to an existing pathology that alters cardiac function. Examples of syndromes that can precede heart failure include myocardial infarction, arrhythmia or infection. These can also cause dilated cardiomyopathy, a condition which accounts for approximately one third of all cases of heart failure. The pathogenesis of heart failure is cyclical and progressive; endogenous mechanisms, which are activated during heart failure in an attempt to counteract the symptoms, actually worsen cardiac function. Cardiac dysfunction, either systolic or diastolic, triggers a decrease in stroke volume and a resultant increase in cardiac output. In healthy individuals the body responds to decreases in cardiac output by initiating the renin-angiotensin-aldosterone system (RAAS) to promote fluid retention, and also by activating the sympathetic nervous system to cause peripheral vasoconstriction. Under normal circumstances this counteracts the imbalance in stroke volume, restoring cardiac output to normal levels. In patients with heart failure the increase in blood volume, together with the heightened peripheral resistance and elevated levels of circulating catecholamines, causes an increased load on the already weakened ventricles with each contraction, and the stroke volume does not return to normal levels. Repeated cycles of this process further weaken the ventricle walls, prompting ventricular hypertrophy and a decreased force of contraction.

Heart Failure Research Products Targets

Products for Heart Failure Research

  1. Cat.No. Product Name Information/Activity
  2. BCC6912 A 61603 hydrobromide 107756-30-9 A 61603 hydrobromide chemical structure
  3. BCC6833 Cirazoline hydrochloride Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full α1A-adrenergic receptor (α1A-AR) agonist (Ki=120 nM) and only a partial agonist at α1B-AR (Ki= 960 nM) and α1D-AR (Ki=660 nM). Cirazoline hydrochloride chemical structure
  4. BCC4333 Oxymetazoline HCl 2315-02-8 Oxymetazoline HCl chemical structure
  5. BCC4335 Phenylephrine HCl (R)-(-)-Phenylephrine hydrochloride is a selective α1-adrenoceptor agonist with pKis of 5.86, 4.87 and 4.70 for α1D, α1B and α1A receptors respectively. Phenylephrine HCl chemical structure
  6. BCC2494 Alfuzosin HCl Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH). Alfuzosin HCl chemical structure
  7. BCC5063 BMY 7378 5-HT<sub>1A</sub> partial agonist,BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. BMY 7378 chemical structure
  8. BCC4324 Carvedilol Carvedilol (BM 14190) is a non-selective β/α-1 blocker. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome. Carvedilol chemical structure
  9. BCC1257 Doxazosin Mesylate Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. Doxazosin Mesylate chemical structure
  10. BCC6683 HEAT hydrochloride 30007-39-7 HEAT hydrochloride chemical structure
  11. BCC6688 Ifenprodil hemitartrate 23210-56-2 Ifenprodil hemitartrate chemical structure

Items 1 to 10 of 148 total